Germline dinucleotide mutation in codon 883 of the RET proto-oncogene in multiple endocrine neoplasia type 2B without codon 918 mutation
- PMID: 9360560
- DOI: 10.1210/jcem.82.11.4508
Germline dinucleotide mutation in codon 883 of the RET proto-oncogene in multiple endocrine neoplasia type 2B without codon 918 mutation
Abstract
The autosomal dominant multiple endocrine neoplasia type 2 syndromes (MEN 2) comprise three clinically distinct entities, MEN 2A, familial medullary thyroid carcinoma and MEN 2B, which share a common clinical feature: medullary thyroid carcinoma (MTC). MEN 2B is considered to have the most aggressive form of MTC. Therefore, early detection of MEN 2B in order to prevent potentially lethal MTC is important. More than 95% of all MEN 2B cases are caused by germline mutation at codon 918 (M918T) in exon 16 of the RET proto-oncogene. In this study, we demonstrate the presence of germline codon 883 mutation (A883F) in 2 of 3 unrelated MEN 2B cases without codon 918 mutation. Our data demonstrate a novel etiologic event which may have roles in predisposition to MEN 2B when present in the germline and in the pathogenesis of sporadic MTC when somatic.
Similar articles
-
Rudolf-Virchow-Preis 1995. The role of RET proto-oncogene mutation analysis in the diagnosis of multiple endocrine neoplasia type 2 (MEN 2) gene carriers and in the discrimination of sporadic and familial medullary thyroid carcinomas and pheochromocytomas.Verh Dtsch Ges Pathol. 1995;79:L-LV. Verh Dtsch Ges Pathol. 1995. PMID: 8600671
-
Two germline missense mutations at codons 804 and 806 of the RET proto-oncogene in the same allele in a patient with multiple endocrine neoplasia type 2B without codon 918 mutation.Jpn J Cancer Res. 1999 Jan;90(1):1-5. doi: 10.1111/j.1349-7006.1999.tb00658.x. Jpn J Cancer Res. 1999. PMID: 10076558 Free PMC article.
-
Analysis of RET proto-oncogene abnormalities in patients with MEN 2A, MEN 2B, familial or sporadic medullary thyroid carcinoma.J Endocrinol Invest. 1998 Jun;21(6):358-64. doi: 10.1007/BF03350771. J Endocrinol Invest. 1998. PMID: 9699127
-
[The RET gene in multiple endocrine neoplasia type 2 (MEN 2)].Nihon Rinsho. 2004 May;62(5):883-8. Nihon Rinsho. 2004. PMID: 15148813 Review. Japanese.
-
RET proto-oncogene mutations in multiple endocrine neoplasia type 2 and medullary thyroid carcinoma.Horm Res. 1997;47(4-6):168-78. doi: 10.1159/000185461. Horm Res. 1997. PMID: 9167949 Review.
Cited by
-
Looking for RET alterations in thyroid cancer: clinical relevance, methodology and timing.Endocrine. 2023 Aug;81(2):206-215. doi: 10.1007/s12020-023-03368-w. Epub 2023 May 17. Endocrine. 2023. PMID: 37195581 Review.
-
RET signaling pathway and RET inhibitors in human cancer.Front Oncol. 2022 Jul 25;12:932353. doi: 10.3389/fonc.2022.932353. eCollection 2022. Front Oncol. 2022. PMID: 35957881 Free PMC article. Review.
-
RET c.1901G>A and Novel SLC12A3 Mutations in Familial Pheochromocytomas.Genes (Basel). 2022 May 12;13(5):864. doi: 10.3390/genes13050864. Genes (Basel). 2022. PMID: 35627249 Free PMC article.
-
Targeting Rearranged during Transfection in Cancer: A Perspective on Small-Molecule Inhibitors and Their Clinical Development.J Med Chem. 2021 Aug 26;64(16):11747-11773. doi: 10.1021/acs.jmedchem.0c02167. Epub 2021 Aug 17. J Med Chem. 2021. PMID: 34402300 Free PMC article. Review.
-
Results and Clinical Interpretation of Germline RET Analysis in a Series of Patients with Medullary Thyroid Carcinoma: The Challenge of the Variants of Uncertain Significance.Cancers (Basel). 2020 Nov 5;12(11):3268. doi: 10.3390/cancers12113268. Cancers (Basel). 2020. PMID: 33167350 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Molecular Biology Databases
